Suppr超能文献

活体供肾再次移植:危险因素与结局

Living-donor kidney retransplantation: risk factors and outcome.

作者信息

El-Agroudy Amgad E, Wafa Ehab W, Bakr Mohamed A, Donia Ahmed F, Ismail Amani M, Shokeir Ahmed A, Shehab El-Dein Ahmed B, Ghoneim Mohamed A

机构信息

Urology & Nephrology Centre, Mansoura University, Mansoura, Egypt.

出版信息

BJU Int. 2004 Aug;94(3):369-73. doi: 10.1111/j.1464-410X.2004.04934.x.

Abstract

OBJECTIVE

To review the results of kidney retransplantation at our centre.

PATIENTS AND METHODS

Between March 1976 and January 2002, 1406 kidneys were transplanted; among these, 54 patients received a second graft (39 men, mean age 32.1 years, sd 8.6). The donors were 48 relatives (mean age 35.4 years, sd 10.1).

RESULTS

The mean (sd, range) duration of the first graft was 49.1 (45.9, 1-192) months and the main cause of these grafts failing was immunological. The mean duration of graft failure was 17.3 (10.5, 5-62) months. The rate of histocompatibility leukocyte antigen (HLA)-A, -B >3 was 16.7% and of haplotype DR matching was 11%. The immunosuppression regimen was mainly based on cyclosporin (75%). There were 33 episodes of acute rejection in 23 patients. The major complications were hypertension (70%), infections (30%) and hepatitis (11%). The overall graft and patient survival was good; 15 grafts (27%) were lost during the follow-up of 1-17 years. Ten patients died, five with a functioning graft. Multivariate analysis showed that donor relationship, primary immunosuppression, duration of first graft and serum creatinine level at 1 year were predictors of graft survival.

CONCLUSION

Renal retransplantation is the treatment of choice in patients who have lost their graft. The use of related living-donors and potent immunosuppression could help to improve the outcome.

摘要

目的

回顾我院肾再次移植的结果。

患者与方法

1976年3月至2002年1月期间,共进行了1406例肾脏移植;其中,54例患者接受了第二次移植(39例男性,平均年龄32.1岁,标准差8.6)。供者为48名亲属(平均年龄35.4岁,标准差10.1)。

结果

首次移植的平均(标准差,范围)时间为49.1(45.9,1 - 192)个月,这些移植失败的主要原因是免疫因素。移植失败的平均时间为17.3(10.5,5 - 62)个月。组织相容性白细胞抗原(HLA)-A、-B>3的比例为16.7%,单倍型DR匹配的比例为11%。免疫抑制方案主要基于环孢素(75%)。23例患者发生了33次急性排斥反应。主要并发症为高血压(70%)、感染(30%)和肝炎(11%)。总体移植和患者生存率良好;在1至17年的随访期间,15例移植肾(27%)丢失。10例患者死亡,5例移植肾仍有功能。多因素分析显示,供者关系、初始免疫抑制、首次移植时间和1年时的血清肌酐水平是移植肾存活的预测因素。

结论

肾再次移植是移植肾失功患者的首选治疗方法。使用亲属活体供者和强效免疫抑制有助于改善预后。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验